Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 787152, 11 pages
http://dx.doi.org/10.1155/2012/787152
Research Article

Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats

1School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan
2Department of Internal Medicine, Pao Chien Hospital, Pingtung City, Pingtung County, Taiwan
3Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Yanpu Township, Pingtung County, Taiwan

Received 25 August 2011; Accepted 7 December 2011

Academic Editor: Carlo Ventura

Copyright © 2012 Chia Ju Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Travers and M. I. McCarthy, “Type 2 diabetes and obesity: Genomics and the clinic,” Human Genetics, vol. 130, no. 1, pp. 41–58, 2011. View at Publisher · View at Google Scholar
  2. H. Tilg and A. R. Moschen, “Adipocytokines: mediators linking adipose tissue, inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 10, pp. 772–783, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. S. Padwal and S. R. Majumdar, “Drug treatments for obesity: orlistat, sibutramine, and rimonabant,” Lancet, vol. 369, no. 9555, pp. 71–77, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. K. C. Ong and H. E. Khoo, “Biological effects of myricetin,” General Pharmacology, vol. 29, no. 2, pp. 121–126, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. C. H. Ko, S. C. Shen, T. J. F. Lee, and Y. C. Chen, “Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells,” Molecular Cancer Therapeutics, vol. 4, no. 2, pp. 281–290, 2005. View at Google Scholar · View at Scopus
  6. I. M. Liu, S. S. Liou, T. W. Lan, F. L. Hsu, and J. T. Cheng, “Myricetin as the active principle of Abelmoschus moschatus to lower plasma glucose in streptozotocin-induced diabetic rats,” Planta Medica, vol. 71, no. 7, pp. 617–621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. I. M. Liu, T. F. Tzeng, S. S. Liou, and T. W. Lan, “Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats,” Life Sciences, vol. 81, no. 21-22, pp. 1479–1488, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. K. C. Ong and H. E. Khoo, “Effects of myricetin on glycemia and glycogen metabolism in diabetic rats,” Life Sciences, vol. 67, no. 14, pp. 1695–1705, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Sclafani and D. Springer, “Dietary obesity in adult rats: similarities to hypothalamic and human obesity syndromes,” Physiology and Behavior, vol. 17, no. 3, pp. 461–471, 1976. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Chantret, A. Rodolosse, A. Barbat et al., “Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for glucose-dependent negative regulation,” Journal of Cell Science, vol. 107, no. 1, pp. 213–225, 1994. View at Google Scholar · View at Scopus
  11. M. Van Heek, D. S. Compton, C. F. France et al., “Diet-induced obese mice develop peripheral, but not central, resistance to leptin,” Journal of Clinical Investigation, vol. 99, no. 3, pp. 385–390, 1997. View at Google Scholar · View at Scopus
  12. J. Y. Zhou, S. W. Zhou, K. B. Zhang et al., “Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats,” Biological and Pharmaceutical Bulletin, vol. 31, no. 6, pp. 1169–1176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  14. K. R. Shanmugasundaram, A. Visvanathan, and K. Dhandapani, “Effect of high-fat diet on cholesterol distribution in plasma lipoproteins, cholesterol esterifying activity in leucocytes, and erythrocyte membrane components studied: importance of body weight,” American Journal of Clinical Nutrition, vol. 44, no. 6, pp. 805–815, 1986. View at Google Scholar
  15. R. D. Abbott, P. W. F. Wilson, W. B. Kannel, and W. P. Castelli, “High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study,” Arteriosclerosis, vol. 8, no. 3, pp. 207–211, 1988. View at Google Scholar · View at Scopus
  16. J. Folch, M. Lees, and G. H. Sloane-Stanley, “A simple method for the isolation and purification of total lipides from animal tissues,” The Journal of Biological Chemistry, vol. 226, no. 1, pp. 497–509, 1957. View at Google Scholar · View at Scopus
  17. E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. C. H. Park, N. Yamabe, J. S. Noh, K. S. Kang, T. Tanaka, and T. Yokozawa, “The beneficial effects of morroniside on the inflammatory response and lipid metabolism in the liver of db/db mice,” Biological and Pharmaceutical Bulletin, vol. 32, no. 10, pp. 1734–1740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Varga, Z. Czimmerer, and L. Nagy, “PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation,” Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 1007–1022, 2011. View at Publisher · View at Google Scholar
  20. A. T. Kraja, M. A. Province, R. J. Straka, J. M. Ordovas, I. B. Borecki, and D. K. Arnett, “Fenofibrate and metabolic syndrome,” Endocrine, Metabolic and Immune Disorders—Drug Targets, vol. 10, no. 2, pp. 138–148, 2010. View at Google Scholar · View at Scopus
  21. F. P. Mancini, A. Lanni, L. Sabatino et al., “Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats,” FEBS Letters, vol. 491, no. 1-2, pp. 154–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Björntorp and L. Sjöström, “Number and size of adipose tissue fat cells in relation to metabolism in human obesity,” Metabolism, vol. 20, no. 7, pp. 703–713, 1971. View at Google Scholar · View at Scopus
  23. F. Paccaud, V. Schlüter-Fasmeyer, V. Wietlisbach, and P. Bovet, “Dyslipidemia and abdominal obesityan assessment in three general populations,” Journal of Clinical Epidemiology, vol. 53, no. 4, pp. 393–400, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. M. J. Malloy and J. P. Kane, “A risk factor for atherosclerosis: triglyceride-rich lipoproteins,” Advances in Internal Medicine, vol. 47, pp. 111–136, 2001. View at Google Scholar · View at Scopus
  25. P. Libby, “Current concepts of the pathogenesis of the acute coronary syndromes,” Circulation, vol. 104, no. 3, pp. 365–372, 2001. View at Google Scholar · View at Scopus
  26. B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow, “High-density lipoprotein function: recent advances,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1792–1798, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. M. G. L. Hertog, E. J. M. Feskens, P. C. H. Hollman, M. B. Katan, and D. Kromhout, “Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study,” Lancet, vol. 342, no. 8878, pp. 1007–1011, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Mandard, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor α target genes,” Cellular and Molecular Life Sciences, vol. 61, no. 4, pp. 393–416, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Ferré, “The biology of peroxisome proliferators-activated receptors: relationship with lipid metabolism and insulin sensitivity,” Diabetes, vol. 53, no. 1, pp. S43–S50, 2004. View at Google Scholar · View at Scopus
  30. M. R. Briggs, C. Yokoyama, X. Wang, M. S. Brown, and J. L. Goldstein, “Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence,” Journal of Biological Chemistry, vol. 268, no. 19, pp. 14490–14496, 1993. View at Google Scholar · View at Scopus
  31. H. N. Ginsberg, “Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 383–392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. C. H. Park, N. Yamabe, J. S. Noh, K. S. Kang, T. Tanaka, and T. Yokozawa, “The beneficial effects of morroniside on the inflammatory response and lipid metabolism in the liver of db/db mice,” Biological and Pharmaceutical Bulletin, vol. 32, no. 10, pp. 1734–1740, 2009. View at Publisher · View at Google Scholar · View at Scopus